Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Clene ( (CLNN) ).
Clene Inc., a company in the biotechnology sector, has entered into an equity distribution agreement with Canaccord Genuity LLC to sell up to $25 million in common stock. As of October 17, 2025, Clene has filed a prospectus supplement to offer an additional $18.88 million in shares, following previous sales totaling approximately $6.12 million, potentially impacting its financial strategy and market presence.
The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
Spark’s Take on CLNN Stock
According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.
Clene’s overall stock score is primarily impacted by its financial instability, with significant challenges in revenue, profitability, and cash flow. Despite strong technical indicators suggesting bullish momentum, the negative valuation metrics due to unprofitability weigh heavily on the stock’s attractiveness. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on CLNN stock, click here.
More about Clene
Average Trading Volume: 113,953
Technical Sentiment Signal: Buy
Current Market Cap: $83.08M
Learn more about CLNN stock on TipRanks’ Stock Analysis page.